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LETTER TO THE EDITOR 
 
Non-alcoholic fatty liver disease (NAFLD) is becoming 
the main chronic hepatitis in Western Countries paral-
leling the increase of obesity and type 2 diabetes. 
NAFLD encompasses a wide spectrum of liver damage 
ranging from simple fatty liver (NAFL) to non-alcohol-
ic steatohepatitis (NASH) with or without fibrosis, but 
the pathogenetic mechanisms involved in the onset and 
progression of NAFLD are not yet fully elucidated [1]. 
Emerging data show that the impairment of intestinal 
barrier, due to alterations in gut microbiota, may play a 
role in NAFLD pathogenesis as well as in disease pro-
gression [2]. In recent years, several studies have focus-
ed on the evaluation of serum zonulin as non-invasive 
marker of intestinal permeability (IP). Zonulin, a 47 
kDa protein, is the inactive precursor of haptoglobin-2; 
it is involved in the regulation of the tight junctions, the 
main driver of intestinal epithelium homeostasis [3]. 
Circulating zonulin has been found increased in differ-
ent pathological conditions such as autism, type 1 and 
type 2 diabetes, metabolic syndrome, and inflammatory 
bowel disease [4], often showing a positive relationship 
with body mass index (BMI), thus indicating the impact 
of obesity in alterations of IP. In the setting of NAFLD, 
available data are scanty and often conflicting. There-
fore, we investigated the potential role of zonulin in dis-
criminating NASH as well as its association with histol-
ogical features of NASH in a cohort of 108 biopsy 
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Table 1. Clinical, biochemical, and histological character-
istics of the study cohort (n = 108). 
 
Variables n = 108 
Age, years 46 ± 12 
BMI (kg/m2) 28.4 ± 4.2 
Waist (cm) 98 ± 11 
Obesity, n (%) 41 (38%) 
Diabetes, n (%) 26 (24%) 
AST (U/L) 34 (31 - 38) 
ALT (U/L) 53 (46 - 64) 
GGT (U/L) 63 (51 - 73) 
Fasting glucose (mg/dL) 100 (90 - 96) 
Fasting insulin (μIU/mL) 15.1 ± 11.3 
Triglycerides (mg/dL) 146 (116 - 149) 
Total cholesterol (mg/dL) 198 (183 - 203) 
HDL-cholesterol (mg/dL) 48 (45 - 49) 
Albumin (g/dL) 4.6 ± 0.4 
Zonulin (ng/mL) 35 ± 19 
Histology 
Fibrosis 
F0/F1 56 (52%) 
F2 21 (19%) 
F3/F4 31 (29%) 
Steatosis 
S1 55 (53%) 
S2 35 (34%) 
S3 14 (13%) 
Ballooning 
0 14 (13%) 
1 51 (49%) 
2 39 (38%) 
Lobular inflammation 
0 24 (23%) 
1 70 (67%) 
2 10 (10%) 
Portal inflammation 
0 57 (55%) 
1 44 (42%) 
2 3 (3%) 
NASH 63 (58%) 
 
Non-alcoholic steatohepatitis is defined as the joint presence of 
hepatic steatosis, ballooning, and lobular inflammation. Data on 
hepatic steatosis, ballooning, lobular inflammation, and portal 
inflammation were available for 104 cases since 4 patients had 
clinical cirrhosis (F4). 
 
 
 
 
proven NAFLD subjects consecutively enrolled at the 
Division of Gastroenterology of the University of Tori-
no. All patients signed a written informed consent to 
participate in the study. The study was approved by the 
ethics committee of the University Hospital Città della 
Salute e della Scienza of Torino and was in accordance 
with the Helsinki Declaration. 
Spearman´s correlation test was used for correlations 
between zonulin and continuous variables. To assess 
differences between groups, the Kruskal-Wallis test or 
the Mann-Whitney U-test were used as appropriate. 
Linear and logistic regression analysis were performed 
to assess the association between circulating zonulin 
and waist circumference or histological characteristics. 
Data were analyzed using the Software MedCalc, ver-
sion 12.0 (Ostend, Belgium). 
Overall, serum zonulin increased proportionally to waist 
circumference (r = 0.22, p = 0.038; Figure 1A) while no 
correlation was found with BMI (r = 0.03, p = 0.741). 
Furthermore, by multivariable regression analysis in-
cluding BMI, age and gender, waist circumference re-
sulted independently associated with serum zonulin lev-
els (t = 2.1, p = 0.038). Despite the lack of magnetic 
resonance imaging for the quantification of visceral fat 
is a limitation of the study, waist circumference is con-
sidered a good surrogate for the estimation of visceral 
fat. Conversely, BMI provides an estimate of total body 
fat. The lack of correlation between zonulin levels and 
BMI is difficult to explain. Probably the different preva-
lence of obesity assessed either by waist circumference 
or by BMI (55% vs. 38%, respectively) may have af-
fected the results. Furthermore, the association between 
zonulin and higher waist circumference is in accordance 
with previous data [5]. 
Concerning histological features, serum zonulin was 
significantly higher in patients with mild/moderate por-
tal inflammation compared to those without (37 ± 15 
ng/mL vs. 46 ± 15 ng/mL, p = 0.005, Figure 1B). A 
similar trend was observed for the degree of ballooning 
even if the statistical significance was not reached prob-
ably due to the small number of cases without this his-
tological characteristic (35 ± 17 ng/mL in patients with-
out compared to 43 ± 16 ng/mL in patients with mild/ 
moderate ballooning, p = 0.084, Figure 1C). Interesting-
ly, when we grouped the cases according to NAS, we 
found that zonulin levels were significantly higher in 
patients with a more severe necroinflammation (37 ± 15 
ng/mL in patients with NAS < 3 vs. 45 ± 16 ng/mL in 
those with NAS ≥ 4, p = 0.013, Figure 1D). Our find-
ings are corroborated by the data reported by Giorgio et 
al., which demonstrated an association between the re-
sults of lactulose and mannitol permeability test (the 
gold standard test for the IP assessment) and liver dis-
ease severity [6]. 
Finally, we observed that circulating zonulin levels 
were not significantly different between patients with 
simple fatty liver and those with NASH (p = 0.827). 
According to our findings, Pacifico et al. did not find a 
significant correlation between serum zonulin and the
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Figure 1. Serum zonulin levels according to waist circumference and the severity of liver disease in patients with non-alcoholic 
fatty liver disease. 
 
Circulating serum zonulin increases according to waist circumference (A) and to the severity of liver disease: portal inflammation (B), 
ballooning (C), and NAFLD activity score (D). 
 
 
 
 
presence of NASH (p = 0.170) [7]. Conversely, in the 
study by Hendy et al., serum zonulin levels were higher 
in non-obese subjects with NAFLD compared to con-
trols and, in the former group, zonulin was able to dis-
criminate NAFL from NASH (7.60 ± 0.91 ng/mL vs. 
4.91 ± 0.46 ng/mL, p < 0.001, respectively) [8]. Differ-
ent clinical features and inclusion criteria (i.e., diabetes 
and other characteristics of metabolic syndrome) or, 
more likely, different analytical methods for the mea-
surement of circulating zonulin may have led to such 
discrepancies. Indeed, a recent paper by Ajamian et al. 
raised some concerns regarding the reproducibility of 
commercial zonulin assays showing that antibodies for 
the detection of zonulin have different antigen specifici-
ty and affinity [9]. Moreover, Vojdani et al. questioned 
the reliability of a single measurement of serum zonulin 
for the evaluation of IP due to its short half-life in the 
bloodstream [10]. 
 
 
CONCLUSION 
 
In our cohort of biopsy-proven NAFLD patients, higher 
serum zonulin levels were associated with higher waist 
circumference suggesting that visceral obesity exerts an 
important effect on the impairment of IP. We could not 
find distinct zonulin levels among subjects with or with-
out NASH but we found that higher zonulin levels are 
associated with a more severe liver necroinflammation. 
Taking into account the potential limitations concerning 
the analytical methods, further studies are warranted to 
clarify the role of zonulin in the setting of NAFLD. 
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